Cure My Disease

Don't miss your cure!

 Log in / Sign up

New eczema duo enters human testing

NCT ID NCT07027527

Ongoing Disease control Sponsor: Apogee Therapeutics, Inc. Source: ClinicalTrials.gov ↗

Summary

This early-stage study is testing a new combination of two drugs, APG777 and APG990, for adults with moderate-to-severe eczema (atopic dermatitis). The main goal is to see if the combination is safe and how the body handles it, comparing it directly to an existing approved drug called dupilumab. About 86 participants will be in the study for up to 82 weeks.

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ATOPIC DERMATITIS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Locations

  • Investigational Site

    Darlinghurst, New South Wales, 2010, Australia

  • Investigational Site

    Kogarah, New South Wales, 2217, Australia

  • Investigational Site

    Westmead, New South Wales, 2145, Australia

  • Investigational Site

    Woolloongabba, Queensland, 4102, Australia

  • Investigational Site

    Carlton, Victoria, 3053, Australia

  • Investigational Site

    East Melbourne, Victoria, 3002, Australia

  • Investigational Site

    Mitcham, Victoria, 3132, Australia

  • Investigational Site

    Parkville, Victoria, 3050, Australia

  • Investigational Site

    Fremantle, Western Australia, 6160, Australia

  • Investigational Site

    London, Ontario, N6H 5L5, Canada

  • Investigational Site

    Peterborough, Ontario, K9J 5K2, Canada

  • Investigational Site

    Richmond Hill, Ontario, L4B 1A5, Canada

  • Investigational Site

    Toronto, Ontario, M4E 1R7, Canada

  • Investigational Site

    Toronto, Ontario, M4W 2N4, Canada

  • Investigational Site

    Toronto, Ontario, M5A 3R6, Canada

  • Investigational Site

    Montreal, Quebec, H1Y 3L1, Canada

  • Investigational Site

    Québec, Quebec, G1W 1S2, Canada

  • Investigational Site

    Sherbrooke, Quebec, J1G 1X9, Canada

  • Investigational Site

    Hamilton, Waitako, 3204, New Zealand

  • Investigational Site

    Auckland, 1051, New Zealand

Conditions

Explore the condition pages connected to this study.

ATOPIC DERMATITIS